Management is buying/committing capital at a price it says the market itself just set against it — cheapness measured ag
The model's full reasoning — Q3 2023 call → NOWe need to determine if management describes deliberately taking on more of its own economic exposure because it believes the outside world is currently mispricing what it already has. That is, does management convey that outsiders are valuing the company or its assets at a level management considers plainly too low relative to something concrete and verifiable, AND that the company is responding by acquiring, retaining, or concentrating that exposure right now rather than shedding it? We need to look for both halves: (1) a mispricing claim anchored to something concrete, and (2) an action already in motion that increases the company's claim on that underpriced value. Scan the transcript. Management talks about cost reductions, revenue guidance, APA deliveries, combination vaccine, etc. They talk about market share, but do they claim that the market is undervaluing the company or its assets? They mention "we believe that this season is a transitional one" and "long-term, both the COVID-19 market and our ability to penetrate the market represent a significant ongoing opportunity." They talk about potential product sales greater than $1 billion annually. But is that a claim that the current valuation is too low? They don't explicitly say "our stock is undervalued" or "the market is mispricing our assets." They talk about future opportunities, but not about a current mispricing relative to a concrete benchmark. They also talk about cost reductions and cash runway. They mention "we have over $960 million across cash accounts receivable as of the third quarter 2023, plus expected cash from the contingent Canadian payment. In addition, we will have $750 million in APA contract value post the 2023-‘24 season deliveries." That might be a statement about cash and receivables, but they don't compare that to the company's market cap or say that the market is undervaluing them. They don't say "our cash and receivables exceed our market cap" or anything like that. They talk about "we are prepared to initiate additional cost reductions" and "we are leaning into and focusing on our opportunity to create a robust and sustainable business platform." That's not about mispricing.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| CTHR | Charles & Colvard, Ltd. | Q1 2023 | 2022-11-06 | F |
| SBGI | Sinclair Broadcast Group, Inc. | Q3 2022 | 2022-11-02 | C |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| TWO | Two Harbors Investment Corp. | Q2 2022 | 2022-08-04 | C+ |
TWO · Q2 2022 → YESThe question is whether management describes the company deliberately taking on more of its own economic exposure because it believes the outside world is currently mispricing what it already has. YES Management anchors the mispricing to concrete, verifiable levels: mortgage spreads at “historically wide” levels (125–150 bp ZV/OAS, far above the non-QE average and the March 31 levels), RMBS coupons now trading at a wide range (2 %–5.5 %) with 300 bp “out-of-the-money” low-coupon pools and 97 bp OAS–ZV spread differential on higher-coupon names.
ESEA · Q4 2022 → YESThe question is whether management describes the company deliberately taking on more of its own economic exposure because it believes the outside world is currently mispricing what it already has. YES Management anchors the undervaluation claim to a concrete, verifiable figure: their own estimate of the fleet’s market value at $666 million (derived from charter-adjusted values and market changes, incorporating the Aegean Express incident), which produces a net asset value of $344 million or >$48 per share.
WD · Q2 2022 → YESThe question is whether management describes the company deliberately taking on more of its own economic exposure because it believes the outside world is currently mispricing what it already has. YES Management anchors the undervaluation claim to a concrete benchmark: CoStar trades at ~30x EBITDA while W&D trades at under 10x despite identical revenue and EBITDA growth rates over 5–10 years. They explicitly state there is “plenty of multiple expansion available to W&D.